A Phase 1/2, Open Label Dose-Escalation And Expansion Trial Of Nkt2152, An Orally Administered HIF2α Inhibitor, To Investigate Safety, Pharmacokinetics, Pharmacodynamics And Clinical Activity In Patients With Advanced Clear Cell Renal Cell Carcinoma

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to test how safe & effective a new oral drug is for patients with a kidney cancer that is resistant to current treatment options or has relapsed (come back). The purpose of this study is to also learn about the maximum dose (# of pills) to give patients that is the most safe & effective.

Medical Condition(s)

clear cell renal cell carcinoma (ccRCC)

Eligibility Criteria

- Age 18 or older
- Documented relapsed or refractory clear cell renal cell carcinoma

Age Range

18 - 120

Healthy Volunteers Needed


Duration of Participation

You will be in the study for up to approximately 3 years (up to one year or more of dosing, and follow-up visits every 6 months for up to 3 years after the last patient in the study has been enrolled). The follow-up period of the study will continue even if you are on other treatments. Your participation in the study may need to be longer to get better answers to the study questions.

Minors Included



Knight Clinical Trials
Phone: 503-494-1080


NiKang Therapeutics, Inc.

Recruitment End


Compensation Provided


Go Back